Merck’s Keytruda Secures FDA Nod For Head And Neck Cancer As First Immunotherapy For Use Around Surgery

All NewsJune 13, 2025

Merck’s Keytruda receives FDA approval for head and neck cancer after showing improved event-free survival in Phase 3 KEYNOTE-689 trial.

We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.

Cookie settings ACCEPT

Manage consent